BTBD10

Across TCGA pan-cancer cohorts, BTBD10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTBD10 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher BTBD10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BTBD10 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, READ, and BLCA are the cancer types where BTBD10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.361	0.777	<.001	24	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	18	view →
BLCA	DFS	Median	All	1.000	0.330	.032	12	view →
HNSC	DFS	Median	II,III,IV	0.194	0.661	.031	9	view →
UCEC	DFS	Median	All	1.000	0.630	.027	6	view →
STAD	DFS	Median	All	0.112	0.492	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BTBD10–LUSC (OS)

Open the LUSC breakdown →